ESMO 2022 | Predictive biomarkers of response to immunotherapy in soft tissue sarcoma

Erlinda Gordon, MD, Cancer Center of Southern California/Sarcoma Oncology Center, Santa Monica, CA, discusses the absence of predictive biomarkers of response to immunotherapy in patients with soft tissue sarcoma. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.